RxDoctor Payments Data

Jon Hammer, MD

Ophthalmology · Lexington, KYNPI 1013449388

Payments from drug & device makers

$2,026in general payments, 2019–2025

Across 60 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$777
  • Glaukos Corporation$265
  • AbbVie$238
  • Mallinckrodt Enterprises LLC$238
  • Bausch & Lomb Americas Inc.$169
  • Genentech USA, Inc.$121
  • plus $218 from 7 others

What the payments were for

  • Food & beverage$2,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,026 in reported general payments places this provider in the 55th percentile of 216 ophthalmology providers in Kentucky.

See all ophthalmology providers in Kentucky

Medicare billing

Part B allowed, 2024
$184,767
Medicare patients
511
Services billed
1,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost59$44,113
LumiganBimatoprost78$35,639
RhopressaNetarsudil Mesylate50$27,324
CombiganBrimonidine Tartrate/Timolol57$17,509
RestasisCyclosporine17$11,823
Travoprost56$11,434
Latanoprost1,058$10,577
Prednisolone Acetate215$9,472
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat492$7,951
Alphagan PBrimonidine Tartrate31$7,188
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$5,886
Timolol Maleate270$3,228
Dorzolamide-TimololDorzolamide/Timolol/Pf17$2,913
Brimonidine Tartrate255$2,597
Pilocarpine Hcl37$2,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$238$72,159183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 216 ophthalmology providers in Kentucky.

Other ophthalmology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →